179 related articles for article (PubMed ID: 3967224)
1. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Bast RC; De Fabritiis P; Lipton J; Gelber R; Maver C; Nadler L; Sallan S; Ritz J
Cancer Res; 1985 Feb; 45(2):499-503. PubMed ID: 3967224
[TBL] [Abstract][Full Text] [Related]
2. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
[TBL] [Abstract][Full Text] [Related]
3. Elimination of malignant clonogenic cells from human bone marrow using multiple myeloid cell-specific monoclonal antibodies and complement.
Hu ZB; Yu ZF; Qiao CN; Ma WL
Chin Med J (Engl); 1991 Aug; 104(8):664-8. PubMed ID: 1914634
[TBL] [Abstract][Full Text] [Related]
4. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
De Fabritiis P; Bregni M; Lipton J; Greenberger J; Nadler L; Rothstein L; Korbling M; Ritz J; Bast RC
Blood; 1985 May; 65(5):1064-70. PubMed ID: 3995166
[TBL] [Abstract][Full Text] [Related]
5. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.
Kvalheim G; Fodstad O; Pihl A; Nustad K; Pharo A; Ugelstad J; Funderud S
Cancer Res; 1987 Feb; 47(3):846-51. PubMed ID: 3492268
[TBL] [Abstract][Full Text] [Related]
6. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
Montgomery RB; Kurtzberg J; Rhinehardt-Clark A; Haleen A; Ramakrishnan S; Olsen GA; Peters WP; Smith CA; Haynes BF; Houston LL
Bone Marrow Transplant; 1990 Jun; 5(6):395-402. PubMed ID: 2369680
[TBL] [Abstract][Full Text] [Related]
7. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
Greenberger JS; Rothstein L; DeFabritiis P; Bregni M; Bast R; Ritz J; Nadler LM; Lipton JM; Sakakeeny MA
Cancer Res; 1985 Feb; 45(2):758-67. PubMed ID: 3967246
[TBL] [Abstract][Full Text] [Related]
8. Elimination of malignant clonogenic breast cancer cells from human bone marrow.
Anderson IC; Shpall EJ; Leslie DS; Nustad K; Ugelstad J; Peters WP; Bast RC
Cancer Res; 1989 Aug; 49(16):4659-64. PubMed ID: 2663144
[TBL] [Abstract][Full Text] [Related]
9. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
Bast RC; Ritz J; Lipton JM; Feeney M; Sallan SE; Nathan DG; Schlossman SF
Cancer Res; 1983 Mar; 43(3):1389-94. PubMed ID: 6337707
[TBL] [Abstract][Full Text] [Related]
10. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement.
Haleem A; Kurtzberg J; Olsen GA; Rhinehardt-Clark A; Leslie DS; Ray L; Smith CA; Peters WP; Haynes BF; Bast RC
Cancer Res; 1987 Sep; 47(17):4608-12. PubMed ID: 3113721
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
Uckun FM; Ramakrishnan S; Houston LL
J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
[TBL] [Abstract][Full Text] [Related]
12. Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma-cell reactive antibody and complement.
Stone MJ; Tong AW; Fay JW; Lee JC
Cancer Detect Prev; 1988; 12(1-6):621-35. PubMed ID: 3180147
[TBL] [Abstract][Full Text] [Related]
13. Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis.
Slaper-Cortenbach IC; Admiraal LG; van Leeuwen EF; Kerr JM; von dem Borne AE; Tetteroo PA
Exp Hematol; 1990 Jan; 18(1):49-54. PubMed ID: 2298269
[TBL] [Abstract][Full Text] [Related]
14. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins.
Stong RC; Youle RJ; Vallera DA
Cancer Res; 1984 Jul; 44(7):3000-6. PubMed ID: 6372999
[TBL] [Abstract][Full Text] [Related]
15. Elimination of malignant tumor cells from human bone marrow using monoclonal antibodies and immunomagnetic beads.
Wang SY; Makl KL; Chen LY; Tzeng CH; Hu CP; Chang C
Anticancer Res; 1993; 13(6A):2281-5. PubMed ID: 8297147
[TBL] [Abstract][Full Text] [Related]
16. Complement depletion in vitro limits monoclonal antibody 6-19-dependent complement-mediated killing of tumor cells in bone marrow.
Duerst RE; Rose D; Frantz CN
Exp Hematol; 1991 Oct; 19(9):863-7. PubMed ID: 1893961
[TBL] [Abstract][Full Text] [Related]
17. Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use.
Kvalheim G; Sørensen O; Fodstad O; Funderud S; Kiesel S; Dörken B; Nustad K; Jakobsen E; Ugelstad J; Pihl A
Bone Marrow Transplant; 1988 Jan; 3(1):31-41. PubMed ID: 3048468
[TBL] [Abstract][Full Text] [Related]
18. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
Humblet Y; Feyens AM; Sekhavat M; Agaliotis D; Canon JL; Symann ML
Cancer Res; 1989 Sep; 49(18):5058-61. PubMed ID: 2548708
[TBL] [Abstract][Full Text] [Related]
19. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
Uckun FM; Stong RC; Youle RJ; Vallera DA
J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
[TBL] [Abstract][Full Text] [Related]
20. Selective removal of clonogenic neoplastic B cells from human bone marrow using anti-HLA-DQ antibodies and complement.
Falkenburg JH; Fibbe WE; Veenhof WF; Koning F; van Eeden G; Voogt PJ; Jansen J
Exp Hematol; 1986 Feb; 14(2):101-7. PubMed ID: 2417877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
